Fruquintinib 1 MG Oral Capsule [Fruzaqla] — RxCUI 2670190
RxNorm drug concept · Semantic branded drug
RxCUI 2670190
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2670190
Official nameFruquintinib 1 MG Oral Capsule [Fruzaqla]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFruzaqla 1 MG Oral Capsule
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)323 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Fruquintinib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Fruzaqla contains the active ingredient fruquintinib, and it's designed specifically for adults whose colorectal cancer has spread and who have already tried several rounds of stan...
- What exactly is Fruzaqla and why was it prescribed to me?
- You take one capsule by mouth once a day — swallowed whole — for the first 21 days of every 28-day cycle. Then you take 7 days off before the next cycle starts. The good news is fo...
- How do I take it, and does it matter if I take it with food?
🕸️ Concept Web — How Fruquintinib 1 MG Oral Capsule [Fruzaqla] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Fruquintinib 1 MG Oral Capsule [Fruzaqla]
RxCUI 2670190 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Fruquintinib
2670179IN
-
Fruquintinib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Fruzaqla
2670185BN
-
Fruzaqla
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fruquintinib Oral Capsule
2670183SCDF -
Fruquintinib Oral Product
2670181SCDG -
Fruquintinib Pill
2670182SCDG -
Fruquintinib Oral Capsule [Fruzaqla]
2670189SBDF -
Fruzaqla Oral Product
2670187SBDG -
Fruzaqla Pill
2670188SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Fruquintinib Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Fruquintinib 1 MG Oral Capsule
2670184SCD -
Fruquintinib 1 MG
2670180SCDC -
Fruquintinib 1 MG [Fruzaqla]
2670186SBDC
-
Fruquintinib 1 MG Oral Capsule
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Fruquintinib 1 MG Oral Capsule
SCD · 2670184 -
Fruquintinib 1 MG
SCDC · 2670180 -
Fruquintinib Oral Capsule
SCDF · 2670183 -
Fruquintinib Oral Product
SCDG · 2670181 -
Fruquintinib Pill
SCDG · 2670182
Brand-Name Concepts
-
Fruquintinib 1 MG [Fruzaqla]
SBDC · 2670186 -
Fruquintinib Oral Capsule [Fruzaqla]
SBDF · 2670189 -
Fruzaqla Oral Product
SBDG · 2670187 -
Fruzaqla Pill
SBDG · 2670188 -
Fruzaqla
BN · 2670185
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2670190 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 63020-0210-21 | 1 BOTTLE in 1 CARTON (63020-210-21) / 21 CAPSULE in 1 BOTTL... | Fruzaqla | Takeda Pharmaceuticals America, Inc. | 2023-11-08 |
| 63020-0225-21 | 1 BOTTLE in 1 CARTON (63020-225-21) / 21 CAPSULE in 1 BOTTL... | Fruzaqla | Takeda Pharmaceuticals America, Inc. | 2023-11-08 |
Observed labelers:
Takeda Pharmaceuticals America, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.